Hence, digenic inheritance should be considered and systematically analyzed in all childhood/AYA cancer patients in whom an identified heterozygous germline MMR gene or POLE/POLD1 PV does not alone explain the age of tumor onset and/or phenotype. This evidence concerns the gene POLE and cancer.